Possible determinism and the real world data

2002 ◽  
Vol 309 (3-4) ◽  
pp. 297-303 ◽  
Author(s):  
Marek Przyborski
Keyword(s):  
Real World ◽  
Real World Data ◽  
World Data ◽  
The Real

scholarly journals Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tae-Hwan Kim ◽  
Hun Do Cho ◽  
Yong Won Choi ◽  
Hyun Woo Lee ◽  
Seok Yun Kang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
Group Performance ◽  
Eastern Cooperative Oncology Group ◽  
Conversion Surgery ◽  
Single Center ◽  
Her2 Positive ◽  
Real World Data ◽  
World Data ◽  
The Real

Abstract Background Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigated the outcomes of trastuzumab-based chemotherapy in a single center. Methods This study analyzed the real-world data of 47 patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single institution. Results With the median follow-up duration of 18.8 months in survivors, the median overall survival (OS) and progression-free survival were 12.8 and 6.9 months, respectively, and the overall response rate was 64%. Eastern Cooperative Oncology Group performance status 2 and massive amount of ascites were independent poor prognostic factors for OS, while surgical resection before or after chemotherapy was associated with favorable OS, in multivariate analysis. In addition, 5 patients who underwent conversion surgery after chemotherapy demonstrated an encouraging median OS of 30.8 months, all with R0 resection. Conclusions Trastuzumab-based chemotherapy in patients with HER2-positive RPMGC in the real world demonstrated outcomes almost comparable to those of the ToGA trial. Moreover, conversion surgery can be actively considered in fit patients with a favorable response after trastuzumab-based chemotherapy.

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

2018 ◽  
Vol 44 (8) ◽  
pp. 1191-1198 ◽  
Author(s):  
Alberto Carmona-Bayonas ◽  
Paula Jiménez-Fonseca ◽  
Isabel Echavarria ◽  
Manuel Sánchez Cánovas ◽  
Gema Aguado ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
National Registry ◽  
Real World Data ◽  
World Data ◽  
The Real

scholarly journals A Novel Prediction Process of the Remaining Useful Life of Electric Vehicle Battery Using Real-World Data

Processes ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 2174
Author(s):  
Xu Wang ◽  
Jian Li ◽  
Ben-Chang Shia ◽  
Yi-Wei Kao ◽  
Chieh-Wen Ho ◽  
...  
Keyword(s):  
Inventory Management ◽  
Real World ◽  
Lithium Ion ◽  
Remaining Useful Life ◽  
Real World Data ◽  
World Data ◽  
The Real ◽  
Battery Capacity ◽  
Useful Life ◽  
Online Process

In modern society, environmental sustainability is always a top priority, and thus electric vehicles (EVs) equipped with lithium-ion batteries are becoming more and more popular. As a key component of EVs, the remaining useful life of battery directly affects the demand of the EV supply chain. Accurate prediction of the remaining useful life (RUL) benefits not only EV users but also the battery inventory management. There are many existing methods to predict RUL based on state of health (SOH), but few of them are suitable for real-world data. There are several difficulties: (1) battery capacity is not easy to obtain in the real world; (2) most of these methods use the individual data for each battery, and the computing processes are difficult to perform in the cloud; (3) there is a lack of approaches for real-time SOH estimating and RUL predicting. This paper adopts several statistical methods to perform the prediction and compars the results of different models on experimental data (NASA dataset). Then, real-world data were implemented for an online process of RUL prediction. The main finding of this research is that the required CPU time was short enough to meet the daily usage after the real-world data was implemented for an online process of RUL prediction. The feasibility and precision of the prediction model can help to support the frequency control in power systems.

Neoadjuvant chemoradiation (NCRT) for esophageal (EC) or gastroesophageal junction cancer (GEJC): A Canadian single institution real-world experience using the CROSS trial regimen.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 25-25
Author(s):  
Sidra Khalid ◽  
Wilma M. Hopman ◽  
Beatrice Preti ◽  
Anna T. Tomiak ◽  
Kiran Virik
Keyword(s):  
Clinical Trial ◽  
Real World ◽  
Gastroesophageal Junction ◽  
Trial Protocol ◽  
Single Institution ◽  
Real World Data ◽  
Trimodality Therapy ◽  
World Data ◽  
The Real ◽  
The Cross

25 Background: NCRT followed by surgery per the CROSS trial regimen is an accepted standard of care in the treatment of EC and GEJC. When treatments are used in the real-world setting, there are often patient, treatment and potential outcome differences compared to the original clinical trial. The study aim was to assess the real-world application and outcomes of the CROSS trial protocol. Methods: A retrospective chart review was undertaken of 83 patients (pts) with EC or GEJC who were treated from June 2012 to June 2018 with CRT. 65 pts were with NCRT intent to proceed to surgery. Pts’ demographics, clinical, pathological, treatment and surgical characteristics were assessed and exploratory analyses were conducted to review these factors and outcomes. Analyses included Chi-square, t-tests and Kaplan-Meier. Results: For pts who underwent NCRT (n = 65): median age was 68 yrs (range 52-80), male 79%, adenocarcinoma 82%, median (m) tumor length 5 cm, GERD 43%, clinical stage II/III 95%, and BMI > 30 in 37%. 80% completed CRT with RT ≥ 41.4 Gy; of these 88% had ≥ 50.4 Gy. Delay/interruption in chemotherapy occurred in 46% and in RT 37%. Pts who underwent surgery were younger (p = 0.04) and weighed more (p = 0.05). mOS was 37 months (M) v 14 M in those who started CRT ≤ 8 weeks (w) from diagnosis v > 8 w (p = 0.10). The median time from CRT to surgery was 8.9 w. 40 pts had surgery with a complete response in 38% and a R0 resection in 98%. Postoperative major and minor complications occurred in 67%. Those < 75 yrs v ≥ 75 yrs had a mOS of 32 M v 15 M respectively (log rank p = 0.46). 25 pts did not get surgery; 28% was due to death/progression. Pts who proceeded to surgery had a mOS of 35 M v 12 M in pts who did not go to surgery (log rank p = 0.002). Further correlative outcome data will be presented. Conclusions: Real-world data in our center showed patient, tumor and treatment differences compared to the CROSS trial protocol. Despite the broadening of eligibility and treatment criteria, survival in a single institution setting is maintained with trimodality therapy compared to NCRT alone. Real-world data is of value in the assessment of therapeutic validity of clinical trial data.

Sign in / Sign up

Export Citation Format

Share Document